Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms, Male × Capecitabine × Clear all

Phase

Phase 2 8 Phase 1/2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 94 Colorectal Neoplasms 58 Stomach Neoplasms 42 Rectal Neoplasms 36 Neoplasm Metastasis 20 Colonic Neoplasms 19 Nasopharyngeal Carcinoma 17 Triple Negative Breast Neoplasms 15 Pancreatic Neoplasms 13 Neoplasms 12 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Gallbladder Neoplasms 7 Cholangiocarcinoma 7 Esophageal Neoplasms 5 Adenocarcinoma Of Esophagus 5 Adenocarcinoma 5 Neuroendocrine Tumors 3 Gastrointestinal Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Digestive System Neoplasms 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3 Recurrence 2 Pathologic Complete Response 2 Liver Neoplasms 2 Intestinal Neoplasms 2 HER2-positive Advanced Breast Cancer 2 HER2 Positive Metastatic Breast Cancer 2 Carcinoma, Hepatocellular 2 Carcinoma, Ductal, Breast 2

Interventions

exemestane 3 Paclitaxel 3 Goserelin 3 pegfilgrastim 2 Tamoxifen 2 Leuprolide 2 Letrozole 2 Cyclophosphamide 2 trastuzumab biosimilar HLX02 1 ribociclib 1 Zoledronic Acid 1 Trastuzumab 1 Taxes 1 Radiotherapy 1 Radiosurgery 1 Pyridoxine 1 Prochlorperazine 1 Palonosetron 1 PF-05280014 1 Ontruzant 1 Ogivri 1 Methotrexate 1 Metformin 1 Lapatinib 1 Ibandronic Acid 1 Granisetron 1 Gonadotropin-Releasing Hormone 1 Fluorouracil 1 Fentanyl 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00301925 2018-08-08

TACT2

Institute of Cancer Research, United Kingdom

Phase 3 Unknown

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡